New incident report
Incident Report Number: 2020-2310
Registrant Reference Number: 2020-CA-000028
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: ONTARIO
PMRA Registration No. 30735 PMRA Submission No. EPA Registration No.
Product Name: Hartz UltraGuard Flea and Tick Drops for Dogs Over 28 kg
Yes
Unknown
Site: Animal / Usage sur un animal domestique
No
Animal's Owner
Dog / Chien
German Shepherd/Greyhound crossbred
1
Female
0.58
75
lbs
Skin
>8 hrs <= 24 hrs / >8 h <= 24 h
>8 hrs <=24 hrs / > 8 h < = 24 h
System
Unknown / Inconnu
No
No
Unknown/Inconnu
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 15-Feb-2020, a 0.58 year old, 75 pound, unknown reproductive status, female, German Shepherd Dog/Greyhound crossbred dog, in unknown condition, with concomitant medical conditions of pruritus, was administered 1.25 tubes of Hartz UltraGuard Flea and Tick Drops for Dogs Over 28 kg (Phenothrin) via the topical route by the animal owner. This is a extra label use as it is an overdose due to multiple tubes applied. On 16-Feb-2020, the dog developed diarrhea and vomiting. The dog had not been evaluated by a veterinarian, no treatment had been performed and the clinical signs continued. Bathing with liquid dish soap to remove the product overdose and continuing use of product monthly, was recommended and environmental flea treatment was discussed. No further information was received in this case.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.